Jonathan Matz

The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics

M. Solèr, Jonathan Matz, Robert G. Townley et al. · European Respiratory Journal · 2001 · 822 citations · Full text

Montelukast for Chronic Asthma in 6- to 14-Year-Old Children

Barbara Knorr, Jonathan Matz, Jonathan A. Bernstein et al. · JAMA · 1998 · 484 citations

Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial

William W. Busse, Eugene R. Bleecker, J Mark FitzGerald et al. · The Lancet Respiratory Medicine · 2018 · 298 citations

Asthma, Rheumatology, Extension Trial +10

Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial

John A. Smith, Michael M. Kitt, Alyn H. Morice et al. · The Lancet Respiratory Medicine · 2020 · 216 citations · Full text

Asthma, Pulmonary Care, Phase 2B +6

Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma

Roland Buhl, M. Solèr, Jonathan Matz et al. · European Respiratory Journal · 2002 · 178 citations · Full text